Probiotic bacteriostatic composition, fiber, non-woven fabric and hygienic product
By mixing Lactobacillus rhamnosus, Bifidobacterium animalis lactum, and Bifidobacterium breve with a hydrophilic oil agent, a probiotic antibacterial fiber is made, which solves the problem of insufficient safety and effectiveness of antibacterial agents in existing hygiene products. It achieves long-lasting antibacterial effect and promotes beneficial bacteria, thereby improving the safety and health benefits of hygiene products.
Patent Information
- Application Number
- CN202411022975.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-29
- Publication Date
- 2024-11-15
AI Technical Summary
Inorganic antibacterial agents used in existing hygiene products pose safety risks, while plant-based antibacterial agents, although safe, have limited effectiveness. Probiotic antibacterial compositions can effectively improve the microecological environment, but existing technologies have failed to effectively utilize the advantages of probiotics.
Inactivated bacterial powders of Lactobacillus rhamnosus LRa05, Bifidobacterium animalis subsp. lactis BLa80, and Bifidobacterium breve BBr60 are mixed with a hydrophilic oil agent to form an antibacterial mixed solution. This solution is then coated onto fibrous materials to produce probiotic antibacterial fibers and nonwoven fabrics, which are used to prepare antibacterial hygiene products.
It enhances the antibacterial effect, strengthens the safety of the host, provides long-lasting antibacterial and stability, promotes the growth of beneficial bacteria, reduces the risk of pathogenic bacteria infection, and improves the microecological environment.
Smart Images

Figure BDA0004967806570000061 
Figure BDA0004967806570000062 
Figure BDA0004967806570000081
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of antibacterial composition and antibacterial sanitary product production, and in particular to a probiotic antibacterial composition, fiber, non-woven fabric and sanitary product. Background Art
[0002] The human body surface, including the skin, respiratory tract, digestive tract, urogenital tract and other parts, has a complex microbial ecosystem, including beneficial bacteria, neutral bacteria and conditional pathogens. These microorganisms are collectively referred to as the human microbiome or microbial community, and they play an important role in maintaining human health, defending against pathogen invasion, promoting nutrient absorption, regulating the immune system, etc. Among them, beneficial bacteria, also known as symbiotic bacteria or probiotics, have a positive impact on human health. For example, Lactobacillus and Bifidobacterium in the intestines help digest food, inhibit the growth of pathogens, produce vitamins, and maintain intestinal barrier function. Certain flora on the skin can also protect the skin from invasion by harmful microorganisms. Neutral bacteria generally have little impact on the host, and their presence helps occupy ecological niches and prevent the overgrowth of pathogens. Under certain conditions, neutral bacteria may also become conditional pathogens. While conditional pathogens coexist peacefully with the human body under normal circumstances, when the human immune system is damaged, the local environment changes, or the flora is imbalanced, these bacteria may become pathogenic factors and cause infection. For example, Escherichia coli is usually harmless in the intestines, but may cause infection in the urinary system. The balance of the human microbiome is essential for maintaining health. When this balance is disrupted, such as due to antibiotic use, disease, environmental changes or changes in lifestyle habits, it may lead to dysbiosis, which may cause various health problems.
[0003] Especially during women's menstrual period or when infants and young children use diapers and other products, specifically, when infants and young children use diapers and other products, urine and other secretions stay on the infants and young children's buttocks for a longer time, leading to the overgrowth of harmful bacteria or pathogenic bacteria, disrupting the balance of the infants and young children's buttocks flora. In addition, infants and young children have low immunity, and these factors together increase the risk of infants and young children suffering from diaper rash, eczema and other diseases, posing a threat to their health.
[0004] At present, there are some sanitary products on the market that claim to have antibacterial and antibacterial functions, such as fabrics with antibacterial effects represented by bamboo fibers, fabrics with inorganic antibacterial agents or plant antibacterial agents added. However, due to the high cost of fabrics with antibacterial effects, the price of sanitary products is high and not economical; inorganic antibacterial agents are easy to damage the health of users due to their low safety; and plant antibacterial agents are relatively safe and harmless and low in cost, but "all medicines are three-point poisons" and also have certain safety hazards. Furthermore, although they can inhibit the growth of harmful bacteria to a certain extent and play a "fire-fighting" role, they do not fundamentally improve the vaginal microecological environment. In contrast, probiotics are a type of active microorganisms that are beneficial to the host. They can colonize on the surface or body of the human body, change the composition of the flora of a certain part of the host, and have a positive impact on health.
[0005] In summary, the development of a safe and effective probiotic antibacterial composition can not only effectively make up for the shortcomings of existing antibacterial composition products, but also use this antibacterial composition to produce fibers, non-woven fabrics and sanitary products with better antibacterial effects, thereby effectively improving the safety of related products. Summary of the invention
[0006] The present invention aims to provide a probiotic antibacterial composition, fiber, non-woven fabric and sanitary products to solve the technical problem that existing sanitary products have potential safety hazards due to the use of fabrics added with inorganic antibacterial agents or plant antibacterial agents.
[0007] To achieve the above-mentioned purpose, the present invention adopts the following technical scheme: a probiotic antibacterial composition, comprising the following raw materials in parts by weight: 1 to 2 parts of Lactobacillus rhamnosus LRa05 powder, 1 to 2 parts of Bifidobacterium animalis lactis subspecies BLa80 powder and 1 to 2 parts of Bifidobacterium breve BBr60 powder.
[0008] Preferably, as an improvement, Lactobacillus rhamnosus LRa05, Bifidobacterium animalis subspecies lactis BLa80 and Bifidobacterium breve BBr60 are all inactivated bacteria.
[0009] Preferably, as an improvement, the present solution also provides a probiotic antibacterial fiber, comprising a fiber material and an antibacterial mixed solution coated on the fiber material; the antibacterial mixed solution is formed by emulsifying a hydrophilic oil agent, the above-mentioned probiotic antibacterial composition and sterile water.
[0010] Preferably, as an improvement, the method comprises the following steps:
[0011] (i) preparing an antibacterial mixed solution: mixing the probiotic antibacterial composition with a hydrophilic oil agent to form an antibacterial mixed solution;
[0012] (ii) Fiber coating stage: the antibacterial mixed solution is evenly coated on the fiber surface to form probiotic antibacterial fiber.
[0013] Preferably, as an improvement, in the (i) stage of preparing the antibacterial mixed solution, the following steps are included:
[0014] S1: Mixing ultrapure water and hydrophilic oil agent: Mix the hydrophilic oil agent with ultrapure water at 50-70°C, stir at 80-101 rpm for not less than 30 minutes to form an emulsion, mix well and cool to 30-50°C for standby use;
[0015] S2: preparing an antibacterial mixed solution: first dissolving the above-mentioned probiotic antibacterial composition (i.e., mixed bacterial powder) in ultrapure water to obtain a bacterial powder suspension, then adding the emulsion obtained in S1 to the bacterial powder suspension with stirring, stirring and mixing to prepare an antibacterial mixed solution, and keeping the solution at 40-45°C in the stirring state for later use.
[0016] Preferably, as an improvement, in the (ii) fiber coating stage, the following steps are included: the antibacterial mixed solution is evenly coated on the fiber with a moisture content of less than 1% and a temperature of 85 to 95°C to form a probiotic antibacterial fiber, wherein the amount of the antibacterial mixed solution used is 4% to 7.5% of the fiber mass (i.e., the mass ratio of the antibacterial mixed solution to the fiber is 40 to 75:1000). As a reference, the amount of the antibacterial mixed solution used in this embodiment is 6.10% of the fiber mass. .
[0017] Preferably, as an improvement, the present solution also provides a probiotic antibacterial non-woven fabric, which is made of the above-mentioned probiotic antibacterial fiber through a spunlace process.
[0018] Preferably, as an improvement, the present scheme also provides a probiotic antibacterial sanitary product, including any one of a sanitary napkin, a diaper, a pull-on pants, a diaper, a sanitary pad, a disinfectant wipe, a cosmetic cotton pad, a makeup remover cotton pad, a facial mask, a surgical gown, a mask or a protective suit prepared from the probiotic antibacterial non-woven fabric described in claim 7.
[0019] Preferably, as an improvement, the probiotic antibacterial non-woven fabric is used as any one or more combinations of the surface layer, the guide layer and the core coating layer of the sanitary napkin and the diaper.
[0020] The principles and advantages of this solution are as follows:
[0021] 1. This solution prepares the obtained probiotic antibacterial composition by combining three probiotics, specifically Lactobacillus rhamnosus, Bifidobacterium animalis milk and Bifidobacterium breve, which not only effectively improves its safety to the host (or user), but also the three probiotics synergize and effectively improve the antibacterial effect of the probiotic antibacterial composition. Specifically, the inventor found through long-term experiments that if any one or two combinations of Lactobacillus rhamnosus, Bifidobacterium animalis milk and Bifidobacterium breve are used alone, the antibacterial effect of the obtained antibacterial composition on Staphylococcus epidermidis (human symbiotic bacteria) and Staphylococcus aureus (pathogenic bacteria) is poor, and if the three are compounded into an antibacterial composition, the antibacterial effect of the composition on Staphylococcus aureus is effectively improved, especially when the mass ratio of Lactobacillus rhamnosus, Bifidobacterium animalis milk and Bifidobacterium breve powder is 2:1:1, the antibacterial rate of Staphylococcus aureus is as high as 90.8%, which effectively avoids the damage caused by pathogenic bacteria infecting the human body.
[0022] 2. Compared with the prior art in which the antibacterial agent is fixed on the fiber, non-woven fabric or sanitary products by immersion or spraying, the antibacterial agent is easily washed away by the liquid and the antibacterial effect is reduced. In this scheme, the antibacterial composition is mixed with the hydrophilic oil agent to form an antibacterial mixed solution, and then evenly coated on the fiber. The hydrophilic oil agent is mostly a long-chain organic compound, and there are both hydrophilic groups and lipophilic groups in its molecules. In the process, the hydrophilic oil agent acts as a medium, and the lipophilic group can adhere tightly to the fiber material, effectively improving the hydrophilicity of the fiber material; and the hydrophilic group combines with water to make the various components in the water adhere to the fiber material evenly and stably, effectively improving the adhesion stability of the antibacterial component on the fiber, thereby effectively avoiding the antibacterial component from being washed away by the solution (such as menstrual blood, urine, sweat, etc.), facilitating the antibacterial component to continue to exert its effect, and improving the long-term antibacterial and antibacterial stability of the antibacterial fiber.
[0023] 3. This solution uses probiotic antibacterial fibers with long-term antibacterial properties to prepare antibacterial non-woven fabrics and even sanitary products, effectively improving the long-term antibacterial properties and antibacterial stability of non-woven fabrics and sanitary products. The antibacterial components in non-woven fabrics and sanitary products are probiotics, which are beneficial microorganisms to the host. They can form a protective antibacterial barrier on the surface or in the human body, change the composition of the flora in a certain part of the host, and have a positive impact on health. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 This is the effect of different concentrations of the probiotic antibacterial composition on macrophage activity in Experimental Example 2 of the present invention.
[0025] Figure 2 This is the effect of different concentrations of the probiotic antibacterial composition on the TNF-α content in macrophages in Experimental Example 2 of the present invention.
[0026] Figure 3 The antibacterial effect of the samples in Experimental Example 3 of the present invention on Staphylococcus epidermidis is shown (the left is the result of the control group, the right is the result of the 5% sample, the dilution rate is 10 3 times). DETAILED DESCRIPTION
[0027] The present invention is further described in detail below in conjunction with examples, but the embodiments of the present invention are not limited thereto. Unless otherwise specified, the technical means used in the following examples and experimental examples are conventional means well known to those skilled in the art, and the materials, reagents, etc. used can be obtained from commercial sources.
[0028] Example 1
[0029] The present invention provides a probiotic antibacterial composition, comprising the following raw materials in parts by weight: 1-2 parts of Lactobacillus rhamnosus LRa05 powder, 1-2 parts of Bifidobacterium animalis lactis subspecies BLa80 powder and 1-2 parts of Bifidobacterium breve BBr60 powder;
[0030] As a reference, Lactobacillus rhamnosus LRa05, Bifidobacterium animalis subsp. lactis BLa80 and Bifidobacterium breve BBr60 are all inactivated bacteria.
[0031] The present invention also provides a probiotic antibacterial fiber, comprising a fiber material and an antibacterial mixed solution coated on the fiber material; the antibacterial mixed solution is formed by emulsifying a hydrophilic oil agent, a probiotic antibacterial composition and sterile water.
[0032] This solution also provides a method for preparing probiotic antibacterial fiber, comprising the following steps:
[0033] (I) Preparation of antibacterial mixed solution: The probiotic antibacterial composition is mixed with a hydrophilic oil agent to form an antibacterial mixed solution, wherein the concentration of the mixed probiotic powder in the antibacterial mixed solution is 1 ~15‰ ; Specifically include the following steps:
[0034] S1: Mixing ultrapure water and hydrophilic oil agent: Mix the hydrophilic oil agent with ultrapure water at 50-70°C, stir at 80-101 rpm for not less than 30 minutes to form an emulsion, mix well and cool to 30-50°C for standby use;
[0035] S2: preparing an antibacterial mixed solution: first dissolving the above-mentioned probiotic antibacterial composition (i.e., mixed bacterial powder) in ultrapure water to obtain a bacterial powder suspension, then adding the emulsion obtained in S1 to the bacterial powder suspension with stirring, stirring and mixing to prepare an antibacterial mixed solution, and keeping the solution at 40-45°C in the stirring state for later use.
[0036] (ii) fiber coating stage: the antibacterial mixed solution is evenly coated on the fiber surface to form probiotic antibacterial fiber;
[0037] Specifically, the method comprises the following steps: uniformly coating the antibacterial mixed solution on the fiber with a moisture content of less than 1% and a temperature of 85 to 95°C to form the probiotic antibacterial fiber, wherein the amount of the antibacterial mixed solution used is 4% to 7.5% of the fiber mass (i.e., the mass ratio of the antibacterial mixed solution to the fiber is 40 to 75:1000). As a reference, the amount of the antibacterial mixed solution used in this embodiment is 6.10% of the fiber mass.
[0038] The present invention also provides a probiotic antibacterial non-woven fabric, which is made from the probiotic antibacterial fiber through a spunlace process.
[0039] The present scheme also provides a probiotic antibacterial sanitary product, including any one of sanitary napkins, diapers, pull-up pants, diapers, sanitary pads, disinfectant wipes, cosmetic cotton pads, makeup remover cotton pads, facial masks, surgical gowns, masks or protective clothing prepared from the above-mentioned probiotic antibacterial non-woven fabric, wherein the probiotic antibacterial non-woven fabric is used as any one or more combinations of the surface layer, guide layer and core coating layer of the sanitary napkin and diaper.
[0040] Experimental Example 1: Antibacterial effects of antibacterial compositions obtained from different probiotic combinations
[0041] Referring to WS / T 650-2019 5.1.1 suspension quantitative antibacterial test, the antibacterial and antimicrobial effects of the compositions obtained by different mass ratios of Lactobacillus rhamnosus LRa05 (strain a), Bifidobacterium animalis subspecies BLa80 (strain b), and Bifidobacterium breve BBr60 (strain c) powder were tested. The test bacteria selected common flora Staphylococcus epidermidis (normal symbiotic bacteria of the human body), Staphylococcus aureus, Candida albicans and Escherichia coli (the latter three are pathogenic bacteria), and the mass ratios of strains in different experimental groups are shown in Table 1.
[0042] Test steps:
[0043] Take the 24h fresh slant culture of the test bacteria, wash it with PBS and dilute it to 5.0×10 5 CFU / mL~4.5×10 6CFU / mL, the bacterial suspension is for later use. Take a sterile test tube, add 5.0mL of sample (specifically, the probiotic antibacterial composition and sterile water are prepared into a suspension with a concentration of 5‰, which is similar to the concentration of mixed bacterial powder in the fiber / non-woven fabric), place it in a 20℃±1℃ water bath for 5 minutes, then add 0.1mL of bacterial suspension, mix quickly and start timing immediately. After the test bacteria and sample have reacted for 1 minute, 1.0mL of the test bacteria and sample mixture is respectively aspirated to inoculate 2 plates, and the culture medium is poured. When the amount of bacteria cannot be counted, make a ten-fold serial dilution with PBS, select the appropriate dilution and aspirate 1.0mL to inoculate 2 plates for live bacterial culture count. At the same time, use PBS instead of the sample for a parallel test as a positive control. The number of colonies recovered in the positive control is 1.0×10 4 CFU / mL~9.0×10 4 CFU / mL. All test samples and control samples were cultured at 36℃±1℃, and the bacterial propagules were cultured for 48h to observe the final results. The test was repeated 3 times and the inhibition rate was calculated.
[0044] Calculation of antibacterial rate:
[0045]
[0046] Where: X---inhibition rate, %;
[0047] Ao---the amount of bacteria recovered in the positive control group, CFU / mL;
[0048] A---The amount of bacteria recovered in the experimental group, CFU / mL.
[0049] If the inhibition rate is ≥50% to 90%, it is judged to have an antibacterial effect; if the inhibition rate is ≥90%, it is judged to have a strong antibacterial effect.
[0050] The test results of the compositions (experimental group) obtained by combining probiotic powders in different mass ratios are shown in Table 1.
[0051] Table 1 Antibacterial effect of antibacterial compositions obtained by different probiotic combinations
[0052]
[0053] Experimental data show that the antibacterial composition obtained by combining different probiotic powder suspensions in this scheme has antibacterial effects on Staphylococcus aureus, Candida albicans and Escherichia coli, but has no antibacterial effect on Staphylococcus epidermidis, indicating that it can effectively inhibit pathogenic bacteria while effectively avoiding damage to symbiotic bacteria. In particular, when the mass ratio of strain a: strain b: strain c powder = 2:1:1, the antibacterial effect of the obtained antibacterial composition is the best, up to 90.8%, with a strong antibacterial effect; and its antibacterial rate for standard Staphylococcus is -3.8%, indicating that it not only does not inhibit the symbiotic Staphylococcus epidermidis, but also promotes its proliferation, with a proliferation rate of up to 3.8%.
[0054] In addition, if any one or a combination of two of Lactobacillus rhamnosus, Bifidobacterium animalis and Bifidobacterium breve is used alone (such as experimental groups 5 to 10), the antibacterial effect of the resulting antibacterial composition on the three pathogenic bacteria is significantly lower than the antibacterial effect of the composition obtained by combining the three probiotic powders in this scheme, indicating that Lactobacillus rhamnosus, Bifidobacterium animalis and Bifidobacterium breve synergistically enhance the effect in the composition, thereby significantly improving the antibacterial effect of the probiotic antibacterial composition and enhancing its barrier effect on the human body.
[0055] Experimental Example 2: Soothing (Determination of the content of inflammatory factors produced by lipopolysaccharide-induced macrophage RAW264.7)
[0056] 1. Project Introduction
[0057] Lipopolysaccharide (LPS) was used to induce the secretion of inflammatory factors in the mouse macrophage cell line RAW 264.7, and an inflammatory response cell model was established to test the effect of the sample on the release level of inflammatory factors (TNF-a). This can be used as one of the evidences to support the soothing and anti-inflammatory effects of cosmetic raw materials.
[0058] 2. Experiment
[0059] 2.1 Experimental Materials and Reagents
[0060] Raw 264.7 mouse macrophages, DMEM complete medium, trypsin, PBS buffer, dexamethasone, MTT kit, MouseTNF-a ELISAKIT kit, cell culture plate.
[0061] 2.2 Main Equipment
[0062] Carbon dioxide cell culture incubator, medical refrigerator, automatic cell counter, medical centrifuge, enzyme-linked immunosorbent analyzer, biological safety cabinet, etc.
[0063] 2.3 Sample preparation
[0064] The sample (probiotic antibacterial composition, ie, mixed bacterial powder) was diluted to the initial concentration using a culture medium, and after being sterilized by filtration through a 0.22-micron filter membrane, was diluted to the test concentration using a culture medium.
[0065] 2.4Raw 264.7 Cell Activity Test
[0066] Raw 264.7 cells were cultured normally under the conditions of 5% CO2 and 37°C. When the cells grew to a confluency of 60-70%, they were digested with trypsin and inoculated into 96-well plates. After the cells adhered for 24 hours, samples of different concentrations to be tested (generally 6-8 concentrations) were added, and the cells were treated respectively. After incubation for 24 hours, the cell activity was measured (MTT method), and at least 3 parallel wells were set for each experimental group.
[0067] The relative cell activity was calculated according to the following formula:
[0068] Relative cell activity / % = absorbance of experimental group / absorbance of blank control group
[0069] Through the cell activity test, safe concentrations (1 to 3) that have no effect on cell activity are selected for the next stage of efficacy testing.
[0070] 2.5 Testing of TNF-a in Raw 264.7 cells induced by LPS
[0071] Raw 264.7 mouse macrophage cell line was cultured normally under the conditions of 5% CO2 and 37°C. When the cells grew to 60-70% confluence, they were digested with trypsin and inoculated in 96-well plates. After the cells adhered for 24 hours, LPS cell culture medium was added to induce the cells to produce inflammatory factors. A blank control group, LPS induced group (model group), sample group and positive control group (dexamethasone) were set up. After incubation for 24 hours, the cell supernatant was collected and stored at low temperature.
[0072] Model Group
[0073] ELISA detection of inflammatory factor TNF-α: During the detection, the supernatant sample was thawed at room temperature and the ELISA detection kit was used for detection according to the operating instructions of the detection kit.
[0074] 2.6 Statistical methods
[0075] The data were statistically processed using professional software, and the t-test was used for statistical comparison. P < 0.05 was considered statistically significant. * represents P < 0.05, ** represents P < 0.01, and *** represents P < 0.001.
[0076] 3. Experimental results
[0077] 3.1 Effects of test samples on cell activity. The results are shown in Table 2 and Figure 1 .
[0078] Table 2 Macrophage activity analysis
[0079]
[0080] The experimental data showed that compared with the blank control group, the cell activity of the samples at a concentration of 0.400% to 3.125% was in the range of 92.43% to 96.13%, which was higher than 90% and had no cytotoxicity.
[0081] 3.2 Effects of test samples on cellular inflammatory factors
[0082] Table 3 Macrophage TNF-α content and significant difference analysis
[0083] Experimental Group concentration Relative content of TNF-α (pg / ml) ± SD Significance Blank control (BC) / 56.82±1.14 / Lipopolysaccharide LPS(M) 1μg / ml 249.66±1.94 / LPS+dexamethasone (PC) 100μg / ml 91.46±2.19 *** LPS+Samples(4) 4mg / ml 162.07±2.37 *** LPS+Samples(2) 2mg / ml 205.11±2.06 *** LPS+Sample(1) 1mg / ml 235.56±2.11 ***
[0084] Note: *** indicates that the TNF-a content in the model group (M) was significantly increased compared with the blank control group (BC) (P<0.001); the TNF-a content in the positive control group was significantly decreased compared with the model group (P<0.001), indicating that the model was successfully established.
[0085] Experimental data show that the positive control dexamethasone at a concentration of 100ug / mL significantly reduces the TNF-α production, and the expression content is 91.46% ± 2.19% (***P<0.001), proving that the experimental model is effective; the sample at a concentration of 4mg / mL significantly reduces the TNF-a production, and the expression content is 162.07pg / mL ± 2.37 (***P<0.001); the sample at a concentration of 2mg / mL significantly reduces the TNF-a production, and the expression content is 205.11pg / mI ± 2.06 (***P<0.001); the sample at a concentration of 1mg / mL reduces the TNF-α production, and the TNF-α expression content is 235.56pg / mL ± 2.11 (***P<0.001).
[0086] It can be seen that the method of determining the content of inflammatory factors (TNF-α) produced by lipopolysaccharide-induced macrophages RAW264.7 shows that the samples have a significant inhibitory effect on inflammatory factors at concentrations of 4 mg / mL, 2 mg / mL and 1 mg / mL, and exhibit dose-dependent anti-inflammatory and soothing effects.
[0087] Experimental Example 3: Experiment on the inhibitory effect of probiotic antibacterial composition on Staphylococcus epidermidis
[0088] The probiotic antibacterial composition in experimental group 2 in experimental example 1 was used, and the suspension quantitative antibacterial test was performed according to WS / T 650-2019 antibacterial and antibacterial effect evaluation method 5.1.1. The experimental steps are as follows:
[0089] 1.1 Culture medium preparation
[0090] LB liquid culture medium: Use a measuring cylinder to measure 100 mL of distilled water and pour it into a 250 mL reagent bottle. Use an analytical electronic balance to weigh 2.5 g of LB broth culture medium and add it to mix well. Sterilize it in a high-temperature and high-pressure steam sterilizer at 121°C for 15 minutes and set aside for use.
[0091] LB solid culture medium - use a measuring cylinder to measure 100mL of distilled water and pour it into a 250mL reagent bottle. Use an analytical electronic balance to weigh 2.5g of LB broth culture medium and 1.5g of agar powder respectively. Add the above weighed reagents and mix well. Sterilize in a high-temperature and high-pressure steam sterilizer at 121℃ for 15min. When the culture medium cools to about 40-50℃, use an electric pipette to draw 15mL of culture medium and pour it into a disposable sterile plate.
[0092] 1.2 Preparation of bacterial suspension
[0093] Take two 12mL bacterial culture tubes, add 3mL LB liquid medium to each, pick a single colony from the solid culture medium of Staphylococcus epidermidis and add it to the liquid culture medium, and use the other tube as a blank control. Place in a constant temperature shaker (37℃, 200rpm) and shake culture overnight (15h).
[0094] 1.3 Sample processing
[0095] Weigh 0.5g sample / 2g sample, 4 portions each, and place them in 50mL centrifuge tubes without sterilization for later use.
[0096] 1.4 Experimental Grouping
[0097] Control (no sample, 10 mL bacterial solution), 5% (0.5 g sample + 9.5 mL bacterial solution), 20% (2 g sample + 8 mL bacterial solution).
[0098] 1.5 Co-culture + plate spread count test
[0099] Dilute the bacterial solution to 10 6 CFU / mL, add the corresponding diluted bacterial solution to the samples according to the group, and the control group is a group without sample. Place in a 37℃ constant temperature incubator and shake and culture for 15 minutes.
[0100] After the culture is completed, the bacterial solution is diluted 10 times with sterile PBS solution, and 100 μL of the dilution is evenly spread on LB solid medium. Place it in a 37°C constant temperature incubator for 18 hours, take it out, take pictures and record the number of colonies.
[0101] Note: The number of colonies is the colony counting result at the corresponding dilution multiple of each group. The counting principle is based on the national standard
[0102] GB4789.2-2016, the colony count is selected between 30CFU and 300CFU. If there is still no colony growth at the minimum dilution multiple, it proves that the sample has a significant antibacterial effect.
[0103] Calculation method for bacterial solution concentration (CFU / mL): colony count × dilution factor × 10 (0.1 mL coating)
[0104] Antibacterial rate = (1-experimental group bacterial solution concentration / control group bacterial solution concentration) × 100%
[0105] Table 4: Inhibitory effect of samples on Staphylococcus epidermidis
[0106] Grouping Colony count Dilution multiple Bacterial concentration (CFU / ml) Antibacterial rate Comparison 58 103 <![CDATA[5.8×10 5 ]]> / 5% 81 103 <![CDATA[8.1×10 5 ]]> -39.66%
[0107] like Figure 3 As shown in Table 4, the antibacterial probiotic composition obtained by combining three probiotics in this scheme not only has no inhibitory effect on Staphylococcus epidermidis, but also has a negative antibacterial rate, indicating that it has a proliferation effect on Staphylococcus epidermidis, with a proliferation rate as high as 39.66%.
[0108] In summary, the probiotic antibacterial composition obtained by combining three probiotics (Lactobacillus rhamnosus LRa05, Bifidobacterium animalis lactis subspecies BLa80, Bifidobacterium breve BBr60) in this scheme not only has a strong inhibitory effect on pathogenic bacteria (such as Staphylococcus aureus), but is also harmless to human symbiotic bacteria (such as Staphylococcus epidermidis), and can also effectively promote the proliferation of symbiotic beneficial bacteria. In particular, when it is used as an antibacterial agent to produce antibacterial fibers, antibacterial non-woven fabrics and antibacterial sanitary products, it effectively inhibits pathogenic bacteria at the contact site, and can also maintain the growth of native beneficial bacteria, and even promote their proliferation, maintaining environmental stability. Taking diapers as an example, the diapers prepared by the antibacterial non-woven fabric of the present scheme have a surface layer, a guide layer and a core coating layer all made of antibacterial non-woven fabric. After infants and young children use the diapers of the present scheme, it can not only effectively inhibit the growth and proliferation of pathogenic bacteria, but also promote the proliferation of beneficial bacteria (such as Staphylococcus epidermidis) on the buttocks of infants and young children, form a protective film on the surface of the buttocks of infants and young children, effectively maintain the stability of the environment of the buttocks of infants and young children, and avoid the growth of harmful bacteria due to the use of diapers, which reduces the resistance of infants and young children, thereby effectively maintaining the health of infants and young children.
[0109] The above is only an embodiment of the present invention, and the common knowledge such as the known specific technical solutions and / or characteristics in the solution is not described in detail here. It should be pointed out that for those skilled in the art, without departing from the technical solution of the present invention, several modifications and improvements can be made, which should also be regarded as the protection scope of the present invention, and these will not affect the effect of the implementation of the present invention and the practicality of the patent. The scope of protection required by this application shall be based on the content of its claims, and the specific implementation methods and other records in the specification can be used to interpret the content of the claims.
Claims
1. A probiotic antibacterial composition, Features: The invention comprises the following raw materials in parts by weight: 1 to 2 parts of Lactobacillus rhamnosus LRa05 powder, 1 to 2 parts of Bifidobacterium animalis lactis subspecies BLa80 powder and 1 to 2 parts of Bifidobacterium breve BBr60 powder.
2. A probiotic antibacterial composition according to claim 1, Features: Lactobacillus rhamnosus LRa05, Bifidobacterium animalis subsp. lactis BLa80 and Bifidobacterium breve BBr60 are all inactivated bacteria.
3. A probiotic antibacterial fiber, Features: The invention comprises a fiber material and an antibacterial mixed solution coated on the fiber material; the antibacterial mixed solution is prepared by emulsifying a hydrophilic oil agent, the probiotic antibacterial composition according to any one of claims 1 to 2 and sterile water.
4. The probiotic antibacterial fiber according to claim 3, Features: The method comprises the following steps: (i) preparing an antibacterial mixed solution: mixing the probiotic antibacterial composition with a hydrophilic oil agent to form an antibacterial mixed solution; (ii) Fiber coating stage: the antibacterial mixed solution is evenly coated on the fiber surface to form probiotic antibacterial fiber.
5. The probiotic antibacterial fiber according to claim 4, Features: In the (i) stage of preparing the antibacterial mixed solution, the following steps are included: S1: Mixing ultrapure water and hydrophilic oil agent: Mix the hydrophilic oil agent with ultrapure water at 50-70°C, stir at 80-101 rpm for not less than 30 minutes to form an emulsion, mix well and cool to 30-50°C for standby use; S2: preparing an antibacterial mixed solution: first dissolving the above-mentioned probiotic antibacterial composition in ultrapure water to obtain a bacterial powder suspension, then adding the emulsion obtained in S1 to the bacterial powder suspension with stirring, stirring and mixing to prepare an antibacterial mixed solution, and keeping the solution at 40-45°C in the stirring state for later use.
6. The probiotic antibacterial fiber according to claim 5, Features: In (ii) the fiber coating stage, the following steps are included: the antibacterial mixed solution is evenly coated on the fiber with a moisture content of less than 1% and a temperature of 85 to 95°C to produce probiotic antibacterial fiber, wherein the amount of the antibacterial mixed solution used is 4% to 7.5% of the fiber mass.
7. A probiotic antibacterial non-woven fabric, Features: The probiotic antibacterial fiber is made by a hydroentanglement process according to any one of claims 4 to 6.
8. A probiotic antibacterial hygiene product, Features: Any one of sanitary napkins, diapers, pull-on pants, diapers, sanitary pads, disinfectant wipes, cosmetic cotton pads, makeup remover cotton pads, facial masks, surgical gowns, masks or protective clothing prepared from the probiotic antibacterial non-woven fabric according to claim 7.
9. A probiotic antibacterial hygiene product according to claim 8, Features: The probiotic antibacterial non-woven fabric is used as any one or more combinations of the surface layer, the guide layer and the core coating layer of sanitary napkins and diapers.
Citation Information
Cited By
Probiotic fiber non-woven fabric, preparation method thereof and probiotic hygienic product
CN119571539A
Post-generation composite fiber with targeted antibacterial effect and preparation method and application thereof
CN120425471A
Composite probiotic formulation for alleviating hyperuricemia and use thereof
WO2026051421A1
